Current Studies

Contact: Dawn Brown, phone 520-742-1833
Email dbrown@neuroresearch.com

Northwest NeuroSpecialists Alzheimer's Disease Clinical Research Studies List:

• Study 1:
  Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease 301: ApoE4 NON-carrier group
  AKA: the ICARA study
  Interventions: Drug: Bapineuzumab/Drug: Placebo Control/Drug: Bapineuzumab/Drug: Bapineuzumab
  Sponsors: Elan Pharmaceuticals
  Phases: Phase III
  URL: http://ClinicalTrials.gov/show/NCT00574132
  www.ICARAstudy.com 1-888-818-MEMORY



• Study 2:
  Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease 302: ApoE4 CARRIER group
  AKA: the ICARA study
  Interventions: Drug: Bapineuzumab/Drug: Placebo Control
  Sponsors: Elan Pharmaceuticals
  Phases: Phase III
  URL: http://ClinicalTrials.gov/show/NCT00575055
  www.ICARAstudy.com 1-888-818-MEMORY



• Study 3: Enrollment Full (Closed)
  A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
  Interventions: Drug: 18F-AV-45
  Sponsors: Avid Radiopharmaceuticals
  Phases: Phase II
  URL: http://ClinicalTrials.gov/show/NCT00702143 ; www.avidrp.com (company website)



• Study 4:
  A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil -202
  Interventions:Drug: PRX-03140/Drug: Placebo
  Sponsors: Epix Pharmaceuticals, Inc.
  Phases: Phase II
  URL: http://ClinicalTrials.gov/show/NCT00672945
  www.trialforAD.com 1-866-521-4455



• Study 5:
  Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease -203
  Interventions: Drug: PRX-03140/Drug: donepezil/Drug: placebo
  Sponsors: Epix Pharmaceuticals, Inc.
  Phases: Phase II
  URL: http://ClinicalTrials.gov/show/NCT00693004
  www.trialforAD.com 1-866-521-4455



• Study 6:
  Efficacy and Safety of T-817MA in Patients with Mild to Moderate Alzheimer's Disease
  Interventions: Drug: T-817MA/Drug: donepezil
  Sponsors: Toyama Chemical Co., Ltd.
  Phases: Phase II
  URL: http://ClinicalTrials.gov/show/NCT00663936



• Study 7:
  Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
  AKA: the IDENTITY study
  Interventions: Drug: LY450139/Drug: LY450139/Drug: placebo
  Sponsors: Eli Lilly and Company
  Phases: Phase III
  URL: http://ClinicalTrials.gov/show/NCT00594568
  www.lillytrials.com




---

Meet our research team

Experience

Recruitment

Current Studies

Patient Forms

Contact Research Site